1. Home
  2. GDL vs ATYR Comparison

GDL vs ATYR Comparison

Compare GDL & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GDL Fund The of Beneficial Interest

GDL

GDL Fund The of Beneficial Interest

HOLD

Current Price

$8.50

Market Cap

94.4M

Sector

Finance

ML Signal

HOLD

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

HOLD

Current Price

$0.89

Market Cap

83.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDL
ATYR
Founded
2006
2005
Country
United States
United States
Employees
N/A
59
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.4M
83.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GDL
ATYR
Price
$8.50
$0.89
Analyst Decision
Hold
Analyst Count
0
8
Target Price
N/A
$4.20
AVG Volume (30 Days)
8.0K
1.3M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
6.02%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$9,628.95
Revenue Next Year
N/A
$156.94
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.71
$0.64
52 Week High
$8.67
$7.29

Technical Indicators

Market Signals
Indicator
GDL
ATYR
Relative Strength Index (RSI) 47.05 47.45
Support Level $8.39 $0.67
Resistance Level $8.61 $1.09
Average True Range (ATR) 0.05 0.07
MACD -0.01 -0.02
Stochastic Oscillator 33.35 26.76

Price Performance

Historical Comparison
GDL
ATYR

About GDL GDL Fund The of Beneficial Interest

GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).

Share on Social Networks: